Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.1414.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.51% | -1.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.93% | -12.16% | |||
| Operating Income | 16.93% | 12.16% | |||
| Income Before Tax | -18.04% | 45.89% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.04% | 45.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.04% | 45.89% | |||
| EBIT | 16.93% | 12.16% | |||
| EBITDA | 17.27% | 12.33% | |||
| EPS Basic | -17.11% | 46.11% | |||
| Normalized Basic EPS | -17.18% | 45.67% | |||
| EPS Diluted | -14.63% | 46.67% | |||
| Normalized Diluted EPS | -17.18% | 45.67% | |||
| Average Basic Shares Outstanding | 0.80% | 0.41% | |||
| Average Diluted Shares Outstanding | 0.80% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||